Skip to content
Screener

NovoCure NVCR Free cash flow

Free cash flow at other companies

Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Nuvation Bio logo
Nuvation BioNUVB
-$43.22M+10.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$66.28M+11.5%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$16.99M-118%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Calculated from NovoCure’s reported figures.

The source filing: NovoCure’s 10-Q, filed July 23, 2026. Open the filing →

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062

FAQ

What is NovoCure's free cash flow?
NovoCure (NVCR) reported free cash flow of $1.22M in Q2 2026.
How has NovoCure's free cash flow changed year-over-year?
NovoCure's free cash flow increased by 105.7% year-over-year, from -$21.42M to $1.22M.
What is the long-term trend for NovoCure's free cash flow?
Over 3 years (2021 to 2025), NovoCure's free cash flow has grown at a 8.9% compound annual growth rate (CAGR), from $58.59M to -$75.68M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about NovoCure's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude